Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4-Reference-Cited by-同舟云学术

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Published:2020-09-15 Issue:21 Volume:63 Page:12542-12573
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Fairhurst Robin A.¹^ORCID,Knoepfel Thomas¹^ORCID,Buschmann Nicole¹,Leblanc Catherine¹,Mah Robert¹,Todorov Milen¹,Nimsgern Pierre¹,Ripoche Sebastien¹,Niklaus Michel¹,Warin Nicolas¹,Luu Van Huy¹,Madoerin Mario¹,Wirth Jasmin¹,Graus-Porta Diana¹,Weiss Andreas¹,Kiffe Michael¹,Wartmann Markus¹,Kinyamu-Akunda Jacqueline¹,Sterker Dario¹,Stamm Christelle¹,Adler Flavia¹,Buhles Alexandra¹,Schadt Heiko¹,Couttet Philippe¹,Blank Jutta¹,Galuba Inga¹,Trappe Jörg¹,Voshol Johannes¹,Ostermann Nils¹,Zou Chao¹,Berghausen Jörg¹,Del Rio Espinola Alberto¹,Jahnke Wolfgang¹^ORCID,Furet Pascal¹

Affiliation:

1. Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01019

Reference86 articles.

1. Fibroblast growth factor signalling: from development to cancer

2. The FGF family: biology, pathophysiology and therapy

3. Fibroblast growth factor receptors as treatment targets in clinical oncology